Skip to content

Anxiety research: what the evidence shows

Research spanning pharmacological, contemplative, and psychedelic-assisted approaches to pathological anxiety.

State of the evidence

Synthesized

Synthesized from 20 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Anxiety, generalized anxiety disorder, GAD, panic disorder, anxiety disorder, then ranked by relevance.

The research consistently points toward anxiety reduction across several intervention types, though the strength of evidence varies widely. Mindfulness-based programs show small-to-moderate anxiety reductions in meta-analyses (effect sizes around 0.38-0.47), and psychedelic-assisted therapy (psilocybin, LSD) shows large reductions in anxiety among cancer patients, with benefits often sustained for months. However, most psychedelic trials are small (12-51 participants), many mindfulness studies are low quality or rely on self-report without blinding, and some findings (e.g., in athletes or low-symptom patients) are inconsistent or absent.

Evidence by study

Direction is which way each study's own result points, not our rating of the study. All 25 matching studies were reviewed; the 20 that directly address the question are shown here.

What the directions mean
Supports:
the study found the intervention worked, or its hypothesis held.
Opposes:
it found the opposite, no benefit or a harm.
No effect:
no significant difference either way.
Mixed:
effects in both directions within the same study.
Unclear:
the abstract does not report a direction.
Study Design Sample size Direction Finding
Meditation Programs for Psychological Stress and Well-being 2014 meta-analysis 3515 Supports Mindfulness meditation programs produced small to moderate reductions in anxiety (effect size 0.38 at 8 weeks, 0.22 at 3-6 months) but were not superior to active treatments like drugs or exercise.
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial 2016 RCT 51 Supports High-dose psilocybin produced large and sustained decreases in anxiety and depressed mood, with about 80% of participants showing clinically significant improvement at 6-month follow-up.
Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders 1992 observational cohort 22 Supports A group mindfulness meditation stress reduction program significantly reduced anxiety and depression scores, with changes maintained at 3-month follow-up and panic symptoms substantially reduced.
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial 2016 RCT 29 Supports Single-dose psilocybin plus psychotherapy produced rapid, substantial, and sustained improvements in anxiety and depression, with 60-80% of participants showing clinically significant reductions at 6.5-month follow-up.
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer 2010 double-blind, placebo-controlled study 12 Supports Psilocybin was safe and associated with a significant reduction in trait anxiety at 1 and 3 months after treatment and improved mood.
A Randomized, Wait-List Controlled Clinical Trial: The Effect of a Mindfulness Meditation-Based Stress Reduction Program on Mood and Symptoms of Stress in Cancer Outpatients 2000 RCT 90 Supports A mindfulness meditation-based stress reduction program significantly reduced anxiety, depression, anger, and confusion subscales and total mood disturbance by 65% compared with wait-list controls.
Safety and Efficacy of Lysergic Acid Diethylamide-Assisted Psychotherapy for Anxiety Associated With Life-threatening Diseases 2014 RCT 12 Supports LSD-assisted psychotherapy significantly reduced state and trait anxiety at 2 months with large effect sizes, and reductions were sustained for 12 months with no serious adverse events.
Mindfulness-based stress reduction for the treatment of adolescent psychiatric outpatients: A randomized clinical trial. 2009 RCT 102 Supports Adolescents receiving MBSR self-reported reduced anxiety, depression, and somatic distress compared with treatment-as-usual controls, with higher rates of diagnostic improvement over 5 months.
Mindfulness-based interventions: an overall review 2021 review Supports Mindfulness-based interventions are effective for improving anxiety among other biopsychosocial conditions, but evidence is inconclusive for several disorders and many included studies are low quality.
Efficacy of Mindfulness-Based Interventions on Anxiety and Sleep Quality in Patients with Breast Cancer: A Systematic Review and Meta-Analysis 2026 systematic review and meta-analysis 3212 Supports Mindfulness-based interventions significantly reduced anxiety compared with control conditions (SMD -0.47), with moderate certainty of evidence, though all studies had some risk of bias concerns.
Mindfulness-Based Cognitive Therapy for Anxiety, Depressive Symptoms and Psychological Distress in Women with Breast Cancer: A Systematic Review and Meta-Analysis of Randomised Controlled Trials 2026 systematic review and meta-analysis 353 Supports MBCT was associated with moderate-to-large short-term reductions in anxiety (g = -0.69), but each estimate rested on only two trials, was not robust to the inferential method, and was rated very low certainty.
Mindfulness-based cognitive therapy in an interdisciplinary rehabilitation setting: effects on depression, anxiety, and hopelessness 2026 observational cohort 130 Mixed Patients with moderate-to-severe depressive symptoms showed significant reductions in anxiety (ES = 0.41) after MBCT, while those with minimal symptoms showed no significant change in anxiety.
Effectiveness of multi-session mindfulness-based interventions on sport performance and competitive anxiety in competitive athletes: a systematic review of controlled trials 2026 systematic review Mixed Across 17 controlled trials, reductions in competitive anxiety from mindfulness-based interventions were less consistent than performance gains and were sometimes equaled by psychological skills training.
The effects of trait mindfulness on Chinese EFL learners’ public speaking anxiety 2026 cross-sectional survey 492 Supports Trait mindfulness was negatively correlated with public speaking anxiety, with psychological capital partially mediating this relationship.
A Comparative Analysis of Stress and Anxiety Reduction Between Working with Clay and Mandala Design Coloring 2026 experimental repeated measures study 20 No effect Guided clay work and mandala coloring produced only small, non-significant decreases in stress and anxiety; the only statistically significant result was a heart rate decrease in the clay work group.
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance 2006 double-blind study 36 Mixed Psilocybin produced acute perceptual changes and labile moods including anxiety, alongside increased mystical experience measures.
Serotonin 1B receptors expressed on forebrain excitatory neurons mediate the post-acute anxiolytic response to psilocybin in mice. 2026 preclinical animal study Supports Psilocybin's post-acute anxiolytic effects in elevated plus maze and novelty suppressed feeding assays were strongly attenuated in mice lacking serotonin 1B receptors on forebrain excitatory neurons.
Acute ayahuasca administration attenuates binge‐like eating and anxiety‐related behaviors in mice subjected to intermittent fasting 2026 preclinical animal study Supports A single oral dose of ayahuasca attenuated anxiety-like behavior in mice subjected to an intermittent fasting binge-like eating protocol.
Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats. 2026 preclinical animal study Supports A single dose of ayahuasca attenuated anxiety- and depressive-like behaviors and neurochemical changes in rats when assessed 15 days later.
The serotonin 1B receptor as a target for the treatment of depression and anxiety 2026 review Supports Argues that the serotonin 1B receptor is a tractable therapeutic target for depression and anxiety, citing preclinical evidence that 5-HT1BR signaling is required for psilocybin's sustained anxiolytic actions.

Points of agreement

  • Mindfulness-based interventions consistently show small-to-moderate anxiety reductions across meta-analyses, RCTs, and observational studies.
  • Psilocybin-assisted therapy in cancer patients consistently produces large anxiety reductions that are often sustained for months.
  • LSD-assisted psychotherapy reduced anxiety in patients with life-threatening illness with effects sustained to 12 months.
  • Preclinical studies converge on serotonin 1B receptor involvement in psilocybin's anxiolytic effects.
  • Several studies note that anxiety benefits are less consistent than other outcomes (e.g., performance, depression) or are not superior to active comparators.

Conflicts

  • Some mindfulness trials report robust anxiety reductions (e.g., 65% mood disturbance reduction, SMD -0.47), while others find no significant anxiety effect (artmaking study) or inconsistent effects (athletes review).
  • Psilocybin is reported to produce large sustained anxiolysis in patient trials, yet one study notes acute anxiety as part of the psilocybin experience.
  • MBCT showed benefit for patients with moderate-to-severe symptoms but no significant anxiety change for those with minimal symptoms.

Gaps

  • Most psychedelic trials have very small samples (12-51 participants) and limited blinding integrity.
  • Durability of anxiety benefits beyond 6-12 months is largely unstudied.
  • Many mindfulness studies are low quality, rely on self-report, and lack adequate blinding.
  • Populations studied are narrow (cancer patients, adolescents, athletes, EFL students); generalizability to other anxiety disorders is unclear.
  • Dose-response relationships for psilocybin and ayahuasca in anxiety are not well characterized.
  • Clinical trial data for selective serotonin 1B receptor agonists in anxiety are lacking.
Browse these studies in the library

Common questions

What does the research agree on about anxiety?
  • Mindfulness-based interventions consistently show small-to-moderate anxiety reductions across meta-analyses, RCTs, and observational studies.
  • Psilocybin-assisted therapy in cancer patients consistently produces large anxiety reductions that are often sustained for months.
  • LSD-assisted psychotherapy reduced anxiety in patients with life-threatening illness with effects sustained to 12 months.
  • Preclinical studies converge on serotonin 1B receptor involvement in psilocybin's anxiolytic effects.
  • Several studies note that anxiety benefits are less consistent than other outcomes (e.g., performance, depression) or are not superior to active comparators.
Where do studies on anxiety conflict?
  • Some mindfulness trials report robust anxiety reductions (e.g., 65% mood disturbance reduction, SMD -0.47), while others find no significant anxiety effect (artmaking study) or inconsistent effects (athletes review).
  • Psilocybin is reported to produce large sustained anxiolysis in patient trials, yet one study notes acute anxiety as part of the psilocybin experience.
  • MBCT showed benefit for patients with moderate-to-severe symptoms but no significant anxiety change for those with minimal symptoms.
What is still unknown about anxiety?
  • Most psychedelic trials have very small samples (12-51 participants) and limited blinding integrity.
  • Durability of anxiety benefits beyond 6-12 months is largely unstudied.
  • Many mindfulness studies are low quality, rely on self-report, and lack adequate blinding.
  • Populations studied are narrow (cancer patients, adolescents, athletes, EFL students); generalizability to other anxiety disorders is unclear.
  • Dose-response relationships for psilocybin and ayahuasca in anxiety are not well characterized.
  • Clinical trial data for selective serotonin 1B receptor agonists in anxiety are lacking.
How we analyze this

This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is Anxiety, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.

A study qualifies only when Anxiety or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.

The full method, including what a person does and does not review, is on the methods page.

Ask your own question in the Research Synthesis Tool

Latest monthly recap: September 2026 →

7,671 articles · 2,685 from the last two years · 3,892,189 participants across 4,391 studies reporting sample size

Common study designs

review 868 systematic review 420 observational cohort 240 randomized controlled trial 1068 theoretical or philosophical paper 396

Compounds studied for anxiety

Data updated

Studies whose primary subject is both the compound and anxiety, with reviews counted by the study design extracted from each abstract. Registered trials are from ClinicalTrials.gov, and each count links to that compound's full trial pipeline. This maps how much research exists, not how well anything works.

Compounds studied for anxiety: studies, meta-analyses and systematic reviews, registered clinical trials, the highest trial phase, and studies from the last two years. Most studies first.
Compound Studies Meta-analyses and systematic reviews Registered trials Highest phase From the last two years
Psilocybin 308 studies 47 meta-analyses and systematic reviews 20 registered trials up to Phase 2 86 from the last two years
Ketamine 198 studies 15 meta-analyses and systematic reviews 21 registered trials up to Phase 4 76 from the last two years
LSD 97 studies 13 meta-analyses and systematic reviews 6 registered trials up to Phase 2 22 from the last two years
MDMA 94 studies 7 meta-analyses and systematic reviews 4 registered trials up to Phase 2 18 from the last two years
Cannabis 78 studies 9 meta-analyses and systematic reviews 20 registered trials up to Phase 2/3 18 from the last two years
Ayahuasca 73 studies 7 meta-analyses and systematic reviews 0 registered trials 13 from the last two years
Esketamine 39 studies 4 meta-analyses and systematic reviews 4 registered trials up to Phase 4 24 from the last two years

Research volume by year

Compare topics →

2,838 studies whose primary subject is anxiety since 2002

Studies about anxiety per year, 2002 to 2026, peaking at 528 in 2026 Bar chart: one bar per year, taller where more studies were published that year. 0 300 600 2005 2010 2015 2020 2025
2026 is partial
Show the numbers
Studies about anxiety per year, 2002 to 2026, peaking at 528 in 2026
Year Studies
2002 5
2003 3
2004 5
2005 7
2006 13
2007 18
2008 16
2009 28
2010 31
2011 30
2012 27
2013 29
2014 41
2015 47
2016 73
2017 94
2018 143
2019 104
2020 146
2021 193
2022 257
2023 328
2024 269
2025 403
2026 528

Research

Synthesize the evidence → Search all →

From Acute MDMA Experiences to Lasting Change: Self-Compassion’s Role in MDMA-Assisted Psychotherapy for Social Anxiety Disorder

October 25, 2026 Christina Chwyl, Mary K. Lear, Sunjeev K. Kamboj et al. preprint

Objectives: Self-compassion may benefit individuals with social anxiety disorder and serve as a mechanism of change within 3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT). Methods: In this secondary analysis of 20 adults with social anxiety disorder who underwent MDMA-AT for social anxiety disorder (NCT05138068), we examined whether both trait self-compassion changes across...

DOI: 10.31234/osf.io/3ard8_v1 (opens in new tab)

Mindfulness-Based Stress Reduction for Generalized Anxiety Disorder: Systematic Review and Meta-Analysis

medRxiv October 24, 2026 Vinicius Vieira Neves, Nana Amma O. O. Larbi, Rebecca L. Acabchuk et al. preprint

Objective: To evaluate the efficacy and safety of Mindfulness-Based Stress Reduction (MBSR) for anxiety symptoms in adults with generalized anxiety disorder (GAD). Design: Systematic review and meta-analysis. Data Sources: CINAHL, Embase, MEDLINE, PsycINFO, Scopus, SocINDEX, ERIC (EBSCO), and ProQuest Dissertations & Theses Global were searched from inception to October 2025; identified trial...

DOI: 10.64898/2026.10.21.26366048 (opens in new tab)

Implicit Self-Death Associations and Symptoms of Depression and Anxiety: A Single-Case Experimental Design

Psychological Reports October 24, 2026 Radiah Maria Belak, Nicholas J. Moberly

Death anxiety may operate as a transdiagnostic process underlying anxiety and depressive symptoms. This study used the Death-Implicit Association Task (D-IAT) to index implicit self-death associations (ISDA) and evaluated a brief mindfulness intervention using a concurrent multiple-baseline design with maintenance across four students with prior anxiety/depressive diagnoses. Across 20 daily...

DOI: 10.1177/00332941261501010 (opens in new tab)

Mindfulness and anxiety among young family caregivers: the mediating roles of psychological flexibility and self-compassion

Frontiers in Psychology October 23, 2026 Yunfu Liu, Shuai Zhong, Cheng-I Yang

Introduction: During critical developmental periods, young family caregivers frequently take on unpaid caregiving for family members who are physically ill, have disabilities, or have mental health conditions. Ongoing caregiving pressure may be associated with a greater risk of anxiety and poorer mental health. Psychological flexibility and self-compassion reflect distinct but interrelated...

DOI: 10.3389/fpsyg.2026.1876251 (opens in new tab)

Effects of a preventive mindfulness intervention on perceived stress and anticipatory anxiety before first clinical training in nursing students: A preregistered randomized controlled trial

Research Square October 22, 2026 Hanae Tainaka, Sachiko Nagaya, Taeko Muramatsu et al. preprint

Abstract Background Clinical training is a significant stressor for nursing students, and those facing their first placement are particularly vulnerable. This preregistered randomized controlled trial (RCT) evaluated whether a 6-week mindfulness program delivered before first clinical training could prevent stress and anxiety. Methods Twenty-nine nursing students were randomly assigned to the...

DOI: 10.21203/rs.3.rs-11214873/v1 (opens in new tab) Full text (opens in new tab)

Beyond Symptom Reduction: Interconnectedness and Self-Transcendent Emotions During MDMA Sessions Predict Flourishing, Not Symptom Change, in Social Anxiety Disorder Treatment

October 20, 2026 Christina Chwyl, Mary K. Lear, Jason B. Luoma preprint

By fostering certain self-transcendent experiences (STE)—those characterized by interconnectedness and other-oriented emotions—3,4-Methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) has been hypothesized to disrupt social anxiety disorder maintenance processes, including negative self-focus, self-criticism, and isolation, thereby enhancing wellbeing. This secondary analysis used...

DOI: 10.31234/osf.io/kbxdq_v1 (opens in new tab)

Mindful Awareness as a Mediator Between Social Appearance Anxiety and Social Media Addiction in Adolescents.

Journal of Psychosocial Nursing and Mental Health Services October 19, 2026 Suheyla Yurt, Şeyma Laloğlu, Nurgul Karakurt et al.

Purpose: Adolescence is a critical period for identity formation and social development, and social media can shape appearance perceptions and social acceptance. Social appearance anxiety may be associated with greater vulnerability to social media addiction, whereas mindful awareness may be linked to lower levels of this risk. The current study tested mindful awareness as a mediator between...

DOI: 10.3928/02793695-20261009-01 (opens in new tab) Full text (opens in new tab)

Research on the construction of an adaptive mindfulness-based cognitive therapy system based on large language models and its efficacy in addressing college students’ anxiety

Frontiers in Psychology October 16, 2026 Yunlong Jia

To handle the problem of resource scarcity and lack of personalization and adaptability in the traditional approach to mindfulness-based cognitive therapy (MBCT) in dealing with college students with anxiety disorders, this study proposes the use of the natural language interface and adaptability properties of large language models (LLMs) to come up with an intelligent college-level MBCT...

DOI: 10.3389/fpsyg.2026.1800278 (opens in new tab)

Effects of Mindfulness-Based Stress Reduction Combined With Perioperative Refined Nursing on Postoperative Sleep Disturbances, Anxiety, and Depression in Patients Undergoing Coronary Artery Bypass Grafting

Actas Españolas de Psiquiatría October 15, 2026 Huajun Yao, Caihong Peng, Min Wu

Background:To assess whether integrating mindfulness-based stress reduction (MBSR) into refined perioperative nursing is associated with improvements in postoperative sleep disturbances, anxiety, and depression in patients undergoing coronary artery bypass grafting (CABG). Methods: We retrospectively reviewed 146 CABG patients treated at Ruijin Hospital, Shanghai Jiao Tong University School of...

DOI: 10.62641/aep.2291 (opens in new tab)

Effect of mindfulness breathing versus acupoint stimulation on anxiety, fatigue, and sleep quality among children undergoing stem cell transplantation: a three-arm randomized controlled trial

Frontiers in Medicine October 14, 2026 N. Magor, Abdelaziz Hendy, S. Ads et al.

Children undergoing hematopoietic stem cell transplantation (HSCT) commonly experience anxiety, fatigue, and sleep disturbances, which may negatively affect their quality of life and recovery. Non-pharmacological interventions, including mindfulness breathing and acupoint stimulation, have emerged as supportive approaches for symptom management. This study evaluated and compared the effects of...

DOI: 10.3389/fmed.2026.1952564 (opens in new tab) Full text (opens in new tab)

Clinical trials

All Anxiety trials →